Literature DB >> 18573926

Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharide.

Debora Pinna1, Pasqua Oreste, Tiziana Coradin, Anna Kajaste-Rudnitski, Silvia Ghezzi, Giorgio Zoppetti, Antonella Rotola, Rafaela Argnani, Guido Poli, Roberto Manservigi, Elisa Vicenzi.   

Abstract

Herpes simplex virus type 1 (HSV-1) and HSV-2 are neurotropic viruses and common human pathogens causing major public health problems such as genital herpes, a sexually transmitted disease also correlated with increased transmission and replication of human immunodeficiency virus type 1 (HIV-1). Therefore, compounds capable of blocking HIV-1, HSV-1, and HSV-2 transmission represent candidate microbicides with a potential added value over that of molecules acting selectively against either infection. We report here that sulfated derivatives of the Escherichia coli K5 polysaccharide, structurally highly similar to heparin and previously shown to inhibit HIV-1 entry and replication in vitro, also exert suppressive activities against both HSV-1 and HSV-2 infections. In particular, the N,O-sulfated [K5-N,OS(H)] and O-sulfated epimerized [Epi-K5-OS(H)] forms inhibited the infection of Vero cells by HSV-1 and -2, with 50% inhibitory concentrations (IC(50)) between 3 +/- 0.05 and 48 +/- 27 nM, and were not toxic to the cells at concentrations as high as 5 muM. These compounds impaired the early steps of HSV-1 and HSV-2 virion attachment and entry into host cells and reduced the cell-to-cell spread of HSV-2. Since K5-N,OS(H) and Epi-K5-OS(H) also inhibit HIV-1 infection, they may represent valid candidates for development as topical microbicides preventing sexual transmission of HIV-1, HSV-1, and HSV-2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18573926      PMCID: PMC2533499          DOI: 10.1128/AAC.00359-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives.

Authors:  Elisa Vicenzi; Alessandra Gatti; Silvia Ghezzi; Pasqua Oreste; Giorgio Zoppetti; Guido Poli
Journal:  AIDS       Date:  2003-01-24       Impact factor: 4.177

2.  Efficacy and safety of a new vaginal contraceptive antimicrobial formulation containing high molecular weight poly(sodium 4-styrenesulfonate).

Authors:  Lourens J D Zaneveld; Donald P Waller; Robert A Anderson; Calvin Chany; William F Rencher; Kenneth Feathergill; Xiao-Hui Diao; Gustavo F Doncel; Betsy Herold; Morris Cooper
Journal:  Biol Reprod       Date:  2002-04       Impact factor: 4.285

Review 3.  Herpes simplex virus infections.

Authors:  R J Whitley; B Roizman
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

4.  Biosynthesis of heparin/heparan sulphate: mechanism of epimerization of glucuronyl C-5.

Authors:  A Hagner-Mcwhirter; U Lindahl; J p Li
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

5.  Structural specificity of heparin binding in the fibroblast growth factor family of proteins.

Authors:  Rahul Raman; Ganesh Venkataraman; Steffen Ernst; V Sasisekharan; Ram Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

Review 6.  The many challenges of facial herpes simplex virus infection.

Authors:  J Esmann
Journal:  J Antimicrob Chemother       Date:  2001-02       Impact factor: 5.790

Review 7.  Challenges in genital herpes simplex virus management.

Authors:  Lawrence Corey
Journal:  J Infect Dis       Date:  2002-10-15       Impact factor: 5.226

8.  Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread.

Authors:  Natalia Cheshenko; Betsy C Herold
Journal:  J Gen Virol       Date:  2002-09       Impact factor: 3.891

Review 9.  The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics.

Authors:  Lawrence Corey; Anna Wald; Connie L Celum; Thomas C Quinn
Journal:  J Acquir Immune Defic Syndr       Date:  2004-04-15       Impact factor: 3.731

10.  Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus.

Authors:  David Lembo; Manuela Donalisio; Marco Rusnati; Antonella Bugatti; Maura Cornaglia; Paola Cappello; Mirella Giovarelli; Pasqua Oreste; Santo Landolfo
Journal:  Antimicrob Agents Chemother       Date:  2008-02-04       Impact factor: 5.191

View more
  11 in total

Review 1.  Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.

Authors:  Allison H Bartlett; Pyong Woo Park
Journal:  Expert Rev Mol Med       Date:  2010-02-01       Impact factor: 5.600

2.  Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers.

Authors:  Anna Luganini; Silvia Fabiole Nicoletto; Lorena Pizzuto; Giovanna Pirri; Andrea Giuliani; Santo Landolfo; Giorgio Gribaudo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

3.  Inhibition of Human Metapneumovirus Binding to Heparan Sulfate Blocks Infection in Human Lung Cells and Airway Tissues.

Authors:  Edita M Klimyte; Stacy E Smith; Pasqua Oreste; David Lembo; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

4.  Sulfated derivatives of Escherichia coli K5 capsular polysaccharide are potent inhibitors of human cytomegalovirus.

Authors:  Beatrice Mercorelli; Pasqua Oreste; Elisa Sinigalia; Giulia Muratore; David Lembo; Giorgio Palù; Arianna Loregian
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

5.  Highly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures.

Authors:  Valeria Cagno; Manuela Donalisio; Andrea Civra; Marco Volante; Elena Veccelli; Pasqua Oreste; Marco Rusnati; David Lembo
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

6.  Sulfated Escherichia coli K5 polysaccharide derivatives inhibit dengue virus infection of human microvascular endothelial cells by interacting with the viral envelope protein E domain III.

Authors:  Peter Vervaeke; Marijke Alen; Sam Noppen; Dominique Schols; Pasqua Oreste; Sandra Liekens
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

Review 7.  Pathogenesis and Inhibition of Flaviviruses from a Carbohydrate Perspective.

Authors:  So Young Kim; Bing Li; Robert J Linhardt
Journal:  Pharmaceuticals (Basel)       Date:  2017-05-04

Review 8.  Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias?

Authors:  Valeria Cagno; Eirini D Tseligka; Samuel T Jones; Caroline Tapparel
Journal:  Viruses       Date:  2019-07-01       Impact factor: 5.048

Review 9.  Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives.

Authors:  Beatrice Mercorelli; David Lembo; Giorgio Palù; Arianna Loregian
Journal:  Pharmacol Ther       Date:  2011-04-28       Impact factor: 12.310

Review 10.  Exploiting herpes simplex virus entry for novel therapeutics.

Authors:  Satvik Hadigal; Deepak Shukla
Journal:  Viruses       Date:  2013-06-10       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.